Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jack W Singer

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 22, 2005
Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxaneJack W Singer
Bioorganic & Medicinal Chemistry Letters|September 7, 2005
Diamino-C,N-diarylpyridine positional isomers as inhibitors of lysophosphatidic acid acyltransferase-betaFeng Hong, David Hollenback, Jack W Singer, et al.
International Journal of Nanomedicine|August 28, 2007
Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugateStewart D Chipman, Fred B Oldham, Gabriella Pezzoni, et al.
Journal of Experimental Pharmacology|May 23, 2018
Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosisSuliman Al-Fayoumi, Taishi Hashiguchi, Yuka Shirakata, et al.
Plos One|September 28, 2019
Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signaturesJack W Singer, Suliman Al-Fayoumi, Jason Taylor, et al.
Journal of Experimental Pharmacology|August 31, 2016
Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitorJack W Singer, Suliman Al-Fayoumi, Haiching Ma, et al.
Oncotarget|October 4, 2018
Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategyJack W Singer, Angela Fleischman, Suliman Al-Fayoumi, et al.
Journal of Hematology & Oncology|December 10, 2016
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignanciesSrdan Verstovsek, Olatoyosi Odenike, Jack W Singer, et al.
Anti-Cancer Drugs|February 16, 2005
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxaneJack W Singer, Scott Shaffer, Brian Baker, et al.
Reproductive Toxicology (Elmsford, N.Y.)|March 8, 2014
Tolerability and toxicological profile of pixantrone (Pixuvri®) in juvenile mice. Comparative study with doxorubicinMonica Longo, Paola Della Torre, Cecilia Allievi, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 22, 2005
Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxaneJack W Singer
Bioorganic & Medicinal Chemistry Letters|September 7, 2005
Diamino-C,N-diarylpyridine positional isomers as inhibitors of lysophosphatidic acid acyltransferase-betaFeng Hong, David Hollenback, Jack W Singer, et al.
International Journal of Nanomedicine|August 28, 2007
Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugateStewart D Chipman, Fred B Oldham, Gabriella Pezzoni, et al.
Journal of Experimental Pharmacology|May 23, 2018
Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosisSuliman Al-Fayoumi, Taishi Hashiguchi, Yuka Shirakata, et al.
Plos One|September 28, 2019
Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signaturesJack W Singer, Suliman Al-Fayoumi, Jason Taylor, et al.
Journal of Experimental Pharmacology|August 31, 2016
Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitorJack W Singer, Suliman Al-Fayoumi, Haiching Ma, et al.
Oncotarget|October 4, 2018
Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategyJack W Singer, Angela Fleischman, Suliman Al-Fayoumi, et al.
Journal of Hematology & Oncology|December 10, 2016
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignanciesSrdan Verstovsek, Olatoyosi Odenike, Jack W Singer, et al.
Anti-Cancer Drugs|February 16, 2005
Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxaneJack W Singer, Scott Shaffer, Brian Baker, et al.
Reproductive Toxicology (Elmsford, N.Y.)|March 8, 2014
Tolerability and toxicological profile of pixantrone (Pixuvri®) in juvenile mice. Comparative study with doxorubicinMonica Longo, Paola Della Torre, Cecilia Allievi, et al.
Pageof 5